Shots: Aegerion (subsidiary of Novelion Therapeutics) to receive $25M upfront, $5M milestones, and royalties on sales of a product. Recordati to get exclusive commercialization rights for Aegerion’s Juxtapid in Japan […]readmore
Tags : lomitapide